Novel Midkine Inhibitor iMDK Inhibits Tumor Growth and Angiogenesis in Oral Squamous Cell Carcinoma
- PMID: 27272788
Novel Midkine Inhibitor iMDK Inhibits Tumor Growth and Angiogenesis in Oral Squamous Cell Carcinoma
Abstract
Midkine is a heparin-binding growth factor highly expressed in various human malignant tumors. However, its role in the growth of oral squamous cell carcinoma is not well understood. In this study, we analyzed the antitumor effect of a novel midkine inhibitor (iMDK) against oral squamous cell carcinoma. Administration of iMDK induced a robust antitumor response and suppressed cluster of differentiation 31 (CD31) expression in oral squamous cell carcinoma HSC-2 cells and SAS cells xenograft models. iMDK inhibited the proliferation of these cells dose-dependently, as well as the expression of midkine and phospho-extracellular signal-regulated kinase in HSC-2 and SAS cells. Moreover, iMDK significantly inhibited vascular endothelial growth factor and induced tube growth of human umbilical vein endothelial cells in a dose-dependent fashion. These findings suggest that midkine is critically involved in oral squamous cell carcinoma and iMDK can be effectively used for the treatment of oral squamous cell carcinoma.
Keywords: Midkine; angiogenesis; iMDK; oral squamous cell carcinoma.
Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Similar articles
-
Inhibition of the growth factor MDK/midkine by a novel small molecule compound to treat non-small cell lung cancer.PLoS One. 2013 Aug 16;8(8):e71093. doi: 10.1371/journal.pone.0071093. eCollection 2013. PLoS One. 2013. PMID: 23976985 Free PMC article.
-
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.Exp Cell Res. 2015 Jul 15;335(2):197-206. doi: 10.1016/j.yexcr.2015.03.019. Epub 2015 Apr 1. Exp Cell Res. 2015. PMID: 25839409 Free PMC article.
-
Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.Int J Oncol. 2005 Dec;27(6):1489-97. Int J Oncol. 2005. PMID: 16273203
-
The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma.Oral Oncol. 2006 Apr;42(4):337-42. doi: 10.1016/j.oraloncology.2005.06.020. Epub 2005 Sep 6. Oral Oncol. 2006. PMID: 16144770 Review.
-
Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors.Curr Opin Hematol. 1999 Jan;6(1):44-50. doi: 10.1097/00062752-199901000-00008. Curr Opin Hematol. 1999. PMID: 9915553 Review.
Cited by
-
Prognosis of Midkine and AT1R expression in resectable head and neck squamous cell carcinoma.Cancer Cell Int. 2023 Sep 24;23(1):212. doi: 10.1186/s12935-023-03060-z. Cancer Cell Int. 2023. PMID: 37743493 Free PMC article.
-
BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma.Cancer Gene Ther. 2024 Nov;31(11):1708-1720. doi: 10.1038/s41417-024-00805-4. Epub 2024 Sep 12. Cancer Gene Ther. 2024. PMID: 39300217 Free PMC article.
-
Midkine is a dual regulator of wound epidermis development and inflammation during the initiation of limb regeneration.Elife. 2020 Jan 14;9:e50765. doi: 10.7554/eLife.50765. Elife. 2020. PMID: 31934849 Free PMC article.
-
Differentiation and roles of bone marrow-derived cells on the tumor microenvironment of oral squamous cell carcinoma.Oncol Lett. 2019 Dec;18(6):6628-6638. doi: 10.3892/ol.2019.11045. Epub 2019 Nov 4. Oncol Lett. 2019. PMID: 31807176 Free PMC article.
-
Significance of serglycin and its binding partners in autocrine promotion of metastasis in esophageal cancer.Theranostics. 2021 Jan 1;11(6):2722-2741. doi: 10.7150/thno.49547. eCollection 2021. Theranostics. 2021. PMID: 33456569 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
